MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging…
Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost…
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
June 20, 2025 19:30 ET Â | Source: Structure Therapeutics Inc. SAN FRANCISCO,…
